Bacillary Dysentery, Shigellosis
Conditions
Brief summary
This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).
Detailed description
The vaccine will be administered on Days 0,14, and 28. Volunteers (10 per group \[8 minimum\]) will receive the same dose at each vaccination dependent upon group assignment. Groups will be divided according to the table below. An interval no less than 1 week will separate the third dose of a group from the first dose of the next group (receiving an increased InvaplexAR dose). Blood, stool, and saliva specimens will be collected at pre-specified intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Ocular tear samples will be collected in groups C and D. Vaccine safety will be actively monitored during vaccination and for 28 days following the third vaccine dose. The decision to advance to the next dose level is based on the safety assessment (not immunogenicity). A dose level with no occurrence of stopping criteria in the 7 days following the last vaccine dose will prompt moving to the next higher level. All safety data will be summarized and reviewed with the research monitor prior to dose escalation. In addition, a report of all safety data will be provided to the sponsor's safety office for informational purposes.
Interventions
BIOLOGICALShigella flexneri 2a InvaplexAR
The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
Sponsors
U.S. Army Medical Research and Development Command
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of enrollment. * Completion and review of comprehension test (achieved \> 70% accuracy). * Signed informed consent document. * Available for the required follow-up period and scheduled clinic visits. * Women: Negative pregnancy test with understanding (through informed consent process) to not become pregnant nor to breastfeed during the study or within 3 months following last vaccination
Exclusion criteria
* Health problems (for example, chronic medical conditions such as psychiatric conditions, diabetes mellitus, hypertension, or any other conditions that might place the subjects at increased risk of adverse events)- study clinicians, in consultation with the PI, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the Research Monitor as appropriate. * Clinically significant abnormalities on physical examination (chronic sinusitis or seasonal rhinitis) which compromise identification and interpretation of potential vaccine associated adverse effects. * Use of immunosuppressive and/or immunomodulative drugs such as corticosteroids or chemotherapeutics that may influence antibody development. * Immunosuppressive illnesses (including IgA deficiency defined by serum IgA below level of detection or \<7mg/dL). * Participation in research involving another investigational product (defined as receipt of an investigational product or exposure to an invasive investigational device) 30 days before planned date of first vaccination or anytime throughout the duration of the study until the last study safety visit. * Positive blood test for HBsAG, HCV, HIV-1/HIV-2. * Clinically significant abnormalities on basic laboratory screening. * Presence of significant unexplained laboratory abnormalities that in the opinion of the PI may potentially confound the analysis of the study results. * Current smoker or smoker in past 1 year ('smoker' defined as daily cigarette, cigar, or pipe use for a period of at least 1 month). Research specific * Structural abnormalities on sinus/nasal cavity examination. * Rhinoplasty. * Nasal polyps. * Nasal ulcers. * Deviated nasal septum. This question is being used to determine whether the volunteer has a clinically significant deviated septum that causes nasal obstruction (thereby causing difficulty breathing), interferes with normal sinus drainage, or obscures visualization of the posterior nasal cavity complicating examination and safety monitoring.. * Chronic sinusitis/rhinitis. * Current or planned use of nasal topical corticosteroids and/or nasal spray medications in the 4 weeks prior to dosing or during the study vaccination period. * Current or recent history (in the past 5 years) of reactive airway disease (asthma), chronic obstructive pulmonary disease, or chronic bronchitis. * History of Bell's palsy. * Chronic use (weekly or more often) of anti-diarrheal, anti-constipation, or antacid therapy (excluding use associated with spicy meals). * Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis; loose or liquid stools on other than an occasional basis. * Personal or family history of inflammatory arthritis. * Positive blood test for HLA-B27. * History of allergy to any vaccine. Prior Exposure to Shigella * Serum IgG titer ≥ 2500 to Shigella flexneri 2a LPS. * History of microbiologically confirmed Shigella infection in the past 3 years. * Received previous experimental Shigella vaccine or live Shigella challenge. * Travel to countries with symptoms of travelers' diarrhea where Shigella or other enteric infections are endemic (most of the developing world) within the past 6 months prior to dosing. * Occupation involving handling of Shigella bacteria currently, or in the past 3 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment Related Adverse Events | 166 days | Number of adverse events related to the vaccine for each arm |
| Antibody Titers Against IgG and IgA Immunizing Antigens | At screening and Days 0, 14, 28, 35, 42, and 56 | Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers \< 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a \> 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer \>10. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | 56 Days | ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ASC response was defined as \> 10 ASCs above baseline. |
| IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | 56 Days | ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 10 μg S. Flexneri 2a Invaplex 9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot. | 9 |
| 50 μg S. Flexneri 2a Invaplex 9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot. | 9 |
| 250 μg S. Flexneri 2a Invaplex 10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot. | 10 |
| 500 μg S. Flexneri 2a Invaplex 10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot. | 10 |
| Total | 38 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Change in employment | 1 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 | 0 | 0 |
| Overall Study | Symptoms post-vaccination | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | 10 μg S. Flexneri 2a Invaplex | Total | 500 μg S. Flexneri 2a Invaplex | 250 μg S. Flexneri 2a Invaplex | 50 μg S. Flexneri 2a Invaplex |
|---|---|---|---|---|---|
| Age, Continuous | 24 years | 28 years | 28 years | 28 years | 34 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 36 Participants | 10 Participants | 9 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 9 Participants | 4 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 28 Participants | 6 Participants | 9 Participants | 6 Participants |
| Region of Enrollment United States | 9 participants | 38 participants | 10 participants | 10 participants | 9 participants |
| Sex: Female, Male Female | 2 Participants | 10 Participants | 2 Participants | 1 Participants | 5 Participants |
| Sex: Female, Male Male | 7 Participants | 28 Participants | 8 Participants | 9 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 9 | 0 / 9 | 0 / 10 | 0 / 10 |
| other Total, other adverse events | 9 / 9 | 9 / 9 | 10 / 10 | 10 / 10 |
| serious Total, serious adverse events | 0 / 9 | 0 / 9 | 0 / 10 | 0 / 10 |
Outcome results
Primary
Antibody Titers Against IgG and IgA Immunizing Antigens
Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers \< 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a \> 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer \>10.
Time frame: At screening and Days 0, 14, 28, 35, 42, and 56
Population: Subjects who received at least 2 vaccine doses were included in the immunology analyses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (Invaplex) | 1345.4 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (Invaplex) | 259.4 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (LPS) | 1902.7 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (LPS) | 259.4 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaB) | 183.4 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaB) | 50.0 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaC) | 336.4 titers |
| 10 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaC) | 70.7 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaB) | 73.5 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaB) | 740.7 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (Invaplex) | 800.0 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaC) | 317.5 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaC) | 2539.8 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (LPS) | 635.0 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (LPS) | 4703.2 titers |
| 50 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (Invaplex) | 4703.2 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaC) | 1728.1 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (LPS) | 4703.2 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (LPS) | 544.3 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaB) | 342.9 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaB) | 85.7 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaC) | 272.2 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (Invaplex) | 5486.4 titers |
| 250 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (Invaplex) | 685.8 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (LPS) | 6400 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (LPS) | 527.8 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (Invaplex) | 606.3 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (Invaplex) | 5571.5 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaB) | 229.7 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaC) | 400.0 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgG (IpaC) | 2599.2 titers |
| 500 μg S. Flexneri 2a Invaplex | Antibody Titers Against IgG and IgA Immunizing Antigens | Serum IgA (IpaB) | 50.0 titers |
Primary
Number of Treatment Related Adverse Events
Number of adverse events related to the vaccine for each arm
Time frame: 166 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10 μg S. Flexneri 2a Invaplex | Number of Treatment Related Adverse Events | 27 Adverse Events |
| 50 μg S. Flexneri 2a Invaplex | Number of Treatment Related Adverse Events | 37 Adverse Events |
| 250 μg S. Flexneri 2a Invaplex | Number of Treatment Related Adverse Events | 41 Adverse Events |
| 500 μg S. Flexneri 2a Invaplex | Number of Treatment Related Adverse Events | 46 Adverse Events |
Secondary
IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses
ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers.
Time frame: 56 Days
Population: Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (Invaplex) | 1.2 fold change |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (Invaplex) | 1.3 fold change |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (LPS) | 1.2 fold change |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (LPS) | 1.1 fold change |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (Invaplex) | 8.6 fold change |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (LPS) | 2.9 fold change |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (LPS) | 3.2 fold change |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (Invaplex) | 8.6 fold change |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (LPS) | 4.0 fold change |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (Invaplex) | 3.7 fold change |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (LPS) | 2.0 fold change |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (Invaplex) | 9.3 fold change |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (LPS) | 2.1 fold change |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgA (Invaplex) | 4.3 fold change |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (Invaplex) | 7.0 fold change |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses | ALS IgG (LPS) | 3.5 fold change |
Secondary
IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses
ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ASC response was defined as \> 10 ASCs above baseline.
Time frame: 56 Days
Population: Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (Invaplex) | 0.5 ASC per 10^6 PBMCs |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (Invaplex) | 1.00 ASC per 10^6 PBMCs |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (LPS) | 0.0 ASC per 10^6 PBMCs |
| 10 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (LPS) | 0.0 ASC per 10^6 PBMCs |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (Invaplex) | 27.0 ASC per 10^6 PBMCs |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (LPS) | 0.0 ASC per 10^6 PBMCs |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (LPS) | 4.0 ASC per 10^6 PBMCs |
| 50 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (Invaplex) | 4.0 ASC per 10^6 PBMCs |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (LPS) | 1.0 ASC per 10^6 PBMCs |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (Invaplex) | 23.0 ASC per 10^6 PBMCs |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (LPS) | 1.0 ASC per 10^6 PBMCs |
| 250 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (Invaplex) | 5.0 ASC per 10^6 PBMCs |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (LPS) | 3.0 ASC per 10^6 PBMCs |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgA (Invaplex) | 41.5 ASC per 10^6 PBMCs |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (Invaplex) | 9.0 ASC per 10^6 PBMCs |
| 500 μg S. Flexneri 2a Invaplex | IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses | ASC IgG (LPS) | 2.0 ASC per 10^6 PBMCs |